trending Market Intelligence /marketintelligence/en/news-insights/trending/aVfAw-6Pe9ucmYg2BiXp9g2 content esgSubNav
In This List

Collegium Pharmaceutical appoints director

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Collegium Pharmaceutical appoints director

Collegium Pharmaceutical Inc. appointed Gwen Melincoff as a class III director, effective Aug. 9, with an initial term expiring at the next annual meeting of shareholders in 2018.

Melincoff is currently managing director at Gemini Advisors LLC and an adviser to Phase 1 Ventures and Verge Genomics.